The randomized play-the-winner (RPW) rule is very useful in clinical trials for patient allocation with two treatments. L. J. Wei (1979, Ann. Statist. 7, 291 296) introduces the generalized Friedman's urn (GFU) model to clinical trials of K treatments (as an extension of the RPW). In this paper, we propose a new adaptive design for multi-arm clinical trials. The proposed adaptive design proportionally depends on the success rates of each treatment, so that a treatment which is doing well is more likely to be assigned in future trials than a treatment which is doing poorly. The new design is more reasonable although it is no longer a GFU model. In the paper we show that the new design has some desirable asymptotic properties and that it has wider and easier applications in practice. Some simulations also support this new design.
INTRODUCTION
Traditional statistical designs for multi-arm clinical trials strive for a balanced allocation of patients to treatments. This is done to minimize the variance of different estimators. However, from an ethical perspective, the balanced allocation may be undesirable, especially when the failure outcomes are rather serious. In this case, it is desirable to have designs which reduce the total number of failure outcomes in a trial while at the same time preserving the capability of making a comparison between treatments. Adaptive designs attempt to capture some type of balance between these two competing issues.
One important family of adaptive designs is the generalized Friedman's urn (GFU) model (GFU is also named as generalized Polya urn (GPU) in the literature). The model can be described as follows. Consider an urn containing K types of particles, representing K``treatments.'' The patients are to be allocated sequentially to the treatments in n stages. At the beginning, the urn contains Y 0 =(Y 0, 1 , Y 0, 2 , ..., Y 0, K ) particles, where Y 0, k denotes the number of the particles of type k, k=1, ..., K. At the stage i, a particle is drawn or split at random from the urn and returned. When a doi: 10.1006Âjmva.2001.1987 , available online at http:ÂÂwww.idealibrary.com on 1 0047-259XÂ01 35.00 type k particle is drawn, the treatment k is then assigned to the ith patient, k=1, ..., K. After observing a random variable ! . When E i #E for all i, the model is called homogeneous and otherwise non-homogeneous. In the sequel, we refer to the matrix D i =[D i (k, j, ! k i ), k, j=1, ..., K] as the rule and E i as the generating matrix at the ith stage. After n splits and generations, the urn composition is denoted by the vector Y n =(Y n, 1 , Y n, 2 , ..., Y n, K ), where Y n, k represents the number of particles in the urn of type k after the n th stage.
The GFU model has biostatistical applications to clinical trials (Wei, 1979) , bioassay , and psychophysics (Rosenberger and Grill, 1997, Hu and Rosenberger, 2000) , etc. A general review can be found in Rosenberger (1996) .
For the non-homogeneous models, it is usually assumed that E i Ä E (see Hu and Rosenberger, 2000) . In both cases, under general conditions (say, irreducible and aperiodic) the matrix E has a unique maximal eigenvalue \ 1 in magnitude which is positive and corresponds to a nonnegative left eigen-
The eigenvector v consists of important quantities in limiting results for adaptive designs associated with E. For a homogeneous generating matrix E, general discussions on the asymptotic theory can be found in Athreya and Karlin (1968) , Athreya and Ney (1972) , Smythe (1996) and Bai and Hu (1999) . Besides, Bai and Hu (1999) also investigate the asymptotic theory for nonhomogeneous models. Wei (1979) discusses GFU with applications to clinical trials of K treatments. In the GFU model considered by him, a success on treatment k generates a particle of type k, and a failure on treatment k generates 1Â(K&1) particles of each of the other K&1 types. However, it doesn't seem adaptive to equally add 1Â(K&1) particles of other K&1 types to the urn when a failure on treatment k is met. In fact, if one treatment performs extremely poorly, then it is unreasonable to add the same number of particles of that type to the urn. Li (1995) proposes a design that only generates particles of the type of the success, and adds nothing to the failures. This leads to a diagonal generating matrix. discuss an urn scheme where a success on treatment k generates a type k particle, and a failure generates particles of the other K&1 types, proportionally to the urn composition at the previous stage. They claim that the theoretical results might be difficult to obtain because the generating matrix is random and dependent on all previous splits and generations.
In this paper, we propose a new adaptive design in Section 2. The new adding scheme generates one particle of type k for a success of treatment k, and for a failure of the treatment k, it generates particles of the other K&1 types proportional to the previous success rates of the K&1 treatments. Though this design is no longer a GFU, it provides a more logical and attractive allocation rule. For the new design, the generating matrices are nonhomogeneous and the random functions are dependent on all previous splits and generations. The new adaptive design seems similar to the one proposed by . However, the asymptotics for the new design are not as difficult to establish as claimed by . In Section 3, we shall establish some desirable asymptotic properties of this design which are important for statistical inference. In Section 4, we report some preliminary simulations. These simulations support the new design.
A NEW ADAPTIVE DESIGN FOR MULTI-ARM CLINICAL TRIALS
One application of the GFU model is the randomized play-the-winner (RPW) rule, which was introduced by Wei and Durham (1978) as an extension to Zelen's (1969) play-the-winner rule. Wei (1979) noted that the RPW rule could be formulated as a GFU model. Suppose that there are two treatments (say, T A and T B ) in the study and that the responses are dichotomous (i.e. success or failure [S and F]). We start with Y 0 =(:, :) particles in the urn. If a type 1 split occurs, the patient is assigned to treatment T A and otherwise, the patient is assigned to treatment T B . Then, the particle is returned to the urn and the patient response is observed. A success on T A or a failure on T B generates a type 1 particle; a success on T B or a failure on T A generates a type 2 particle.
Under the simple population model
it is easy to see that we have a GFU with
According to Athreya and Karlin (1968) , the proportion of patients assigned to each treatment and the proportions of each type of particle are asymptotically equal to each other, i.e.,
as n Ä , where N n, 1 denotes the number of times that the treatment 1 is selected in the first n splits. Wei (1979) discussed the following GFU with applications to clinical trials of K treatments (as an extension of the RPW of two treatments).
Adaptive Design 1 (GFU Model 1, Wei, 1979) . Starting from Y 0 = (Y 0, 1 , ..., Y 0, K ), when a type k splits (randomly from the urn), we assign the patient to the treatment k and observe the patient's response. A success on treatment k adds a particle of type k to the urn and a failure on treatment k adds 1Â(K&1) particles for each of the other K&1 types. Let X k j =1 if the jth split is type k, and 0 otherwise. Let T j =1 if the response of the jth trial is a success, 0 otherwise.
We have a GFU with
It follows from Athreya and Karlin (1968) that
where v
(1)
1Âq j is the kth element of the left eigenvector corresponding to the largest eigenvalue \ 1 =1 of E (1) . When there is a failure on treatment k, it should be more reasonable to add more articles corresponding to better treatment among the other K&1 treatments. Thus, the following adaptive design is proposed.
Adaptive Design 2 (GFU Model 2). If the success probabilities of treatments were known, while one particle of the same type is added to the urn, it seems more reasonable to add fractional particles for the other K&1 types, proportional to the success rates P, i.e., to add p j Â (
particles of type j to the urn, for j{k, when the response is a failure on treatment k. Define M= p k , we have a GFU with the generating matrix
Results of Karlin (1967, 1968) yield
is the k th element of the left eigenvector corresponding to the largest eigenvalue of E (2) and
However, the GFU model 2 is not realistic since P=( p 1 , ..., p K ) is in fact unknown. But it gives an idea to improve the adaptive design. We now propose the following adaptive design which is more realistic and easy to implement. To clearly describe the new design, we introduce some notation. Write N n =(N n, 1 , ..., N n, K ) and S n =(S n, 1 , ..., S n, K ), where N n, k denotes the number of times that the k th treatment is selected in the first n splits, and S n, k denotes the number of successes of the k th treatment in the N n, k trials,
Here, adding 1 in both the numerator and denominator does not affect our asymptotic results, it is only for avoiding the nonsense case of 0Â0. It is easy to see that N 0 =(0, ..., 0), S 0 =(0, ..., 0) and, R 0 =(1, ..., 1). Based on R n , an estimation of P, we have the following design:
Adaptive Design 3 (The Proposed Model). At the nth stage, if the response is a success on the treatment k, then add one particle of type k. And if it is a failure, then add R n&1, j Â(M n&1 &R n&1, k ) particles of type j to the urn for all j{k, where M n&1 = K j=1 R n&1, j . Note that the new design is no longer a GFU model since the expected increment of particles of each type is different from stage to stage. The conditionally expected increment of the particles of the n th step given the R n&1, k 's is
Comparing the above three adaptive designs, the following three points are easily seen.
(i) When K=2, the Adaptive Designs 1, 2, and 3 are all the RPW rule. So all of these designs are extensions of RPW rule to K treatments.
(ii) For Designs 1 and 2, when K>2, notice that for any k{ j,
GFU model 2 is more ethical than GFU model 1, because more patients will be assigned to a better treatment in GFU model 2 than those in GFU model 1.
(iii) For the adaptive design 3, the generating matrix E n differs for each n and depends on all previous splits and generations. The asymptotic theorems of Athreya and Karlin (1968) , Smythe (1996) , and Bai and Hu (1999) do not apply here.
ASYMPTOTIC PROPERTIES
Using the notation defined in the last section, we shall establish the following results.
is the k th element of the left eigenvector corresponding to the largest eigenvalue \ 1 =1 of E (2) .
In the proof of Theorem 1, one can easily see that S n, k is a sum of independent and identically distributed (iid) random variables with random number of terms and that R n, k is a consistent estimator of p k . As a by-product, we have the following corollary.
Corollary 2. Under the conditions of Theorem 1, we have
Note. In Corollary 2, if the allocation N n is defined by stopping times { k i other than those as in Adaptive Design 3, the conclusion of Corollary 2 remains true provided that the trial responses T n =(T 1 n , ..., T K n ) are an iid sequence of K vectors of independent Bernoulli trials, where the vector v (2) should be redefined as the limit of N n Ân and T n is defined later prior to the proof of Lemma 1. Note that the first task of clinic trials is to detect the best treatment as fast as possible and the ethical perspective is only the second. Therefore, if the experimenter over-emphasizes the success rates, then success rates of some treatment cannot be well estimated due to less allocation of patients. Now, we return to our proofs of the main results. At first, we give a mathematical description of the Adaptive 
Then, we have the recursive formula
and
It is trivial that
is independent of F$ j and Y j # F j . Before processing with the proofs of Theorem 1, we first establish the following preliminary results.
Proof. Using the notation introduced above, we have N n, k = n j=1 X k j . We first show that N n, k Ä , a.s. \1 k K.
Define the event A n, k =[X k n =1], for k=1, 2, ..., K and n 1. Then,
By the generalized Borel Cantelli lemmas (see, e.g., Chow and Teicher, 1997, p. 249), it follows from (1) that
which simply implies that,
is a sequence of strictly increasing stopping times with respect to the _-field
This shows that [3
..] is an iid sequence of Bernoulli trials with success probability p k . By the Strong Law of Large Numbers, we have 3
we conclude that S n, k ÂN n, k Ä p k , a.s. Then, the proof of Lemma 1 is complete.
Remark on the Proof of Corollary 2. Using the notation of Lemma 1, for a set of constants [%
where C(k) denote all possibilities of integers that the stopping times
(ii) there do not exist four integers 1 k 1 <k 2 K and 1 i 1 m k 1 , 1 i 2 m k 2 , such that j
The above equations show that the random variables [3
Using the conclusion of Theorem 1 and the dominated convergence theorem,
This proves Corollary 2.
Proof. We first show that \k, Y n, k Ä a.s. with the same order of n. 
The k th component of the second term in the above limit is
where
In the proof of the last inequality, we have used the fact that for each j,
A dual consequence of the above is that
Similarly define
Then by the fact that |Z $ n, k | 1, we can similarly show that
Together with (2) and (3), we have 0<lim inf
This finishes the proof of Lemma 2.
where the matrix norm &A& is the maximum absolute value of the entries of A.
Proof. Recall the proof of Lemma 1. By the Law of Iterated Logarithm, we have 3 (-log log nÂn) . Again using the relation S n, k ÂN n, k =3 k N n, k and applying Lemma 2, we have, for each k=1, ..., K,
a.s., from which the lemma follows.
Lemma 4 (Burkholder, 1973) . Let [Y n ] be a complex martingale difference sequence with respect to the increasing _-field [F n ]. Then for p>1
In the sequel, for convenience of notation, without loss of generality, we only give the proofs of Theorem 1 for the case K=3 in the following discussion. Now, the generating matrix is then
n , n=0, 1, 2, ..., ] be the process of particles composition in the urn of GFU Model 2 which starts with Y (2) 0 =(:, :, :). Then we have
Proof of Theorem 1. We only need to prove the first conclusion of the theorem, since the second is a consequence of (4) and the first conclusion of the theorem. From the definition of the Adaptive Design 3, we have
where Q n =X n D n &Y n&1 E n Â(3:+n&1) and W n&1 =I+E (2) Â(3:+n&1). Repeating the process (5), we have
The proof of the theorem will be complete if one can show that Before proceeding with our proofs, we first look into the asymptotic behavior of the matrices W i } } } W n&1 . Write the Jordan decomposition of the matrix E (2) as
Noticing that W j =I+E (2) Â(3:+ j ), we have
3:
It is not difficult to verify that for both choices of
Therefore, we have
We now prove (3:+n) &1 (III ) Ä 0 a.s. Note that (III) is a sum of martingale differences. Thus, by the Burkholder inequality, by choosing m>2Â(1&\), we have
Note that
Therefore, we obtain from (8)
The right hand side is summable and hence the assertion that (3:+n)
&1
(III ) Ä 0 a.s. is proved. By Lemma 3 and the fact that (E i &E (2) ) 1=0, we have
This proves that (3:+n) &1 (II ) Ä 0 a.s. and consequently, the proof of the theorem is complete.
Some concluding comments should be noted: (i) From Theorem 1, Adaptive Design 3 has the same asymptotic limits as Adaptive Design 2. The expected survival probability (asymptotically) of Adaptive Designs 2 and 3 is
while it is
for the design 1. Simple calculation yields the difference,
Thus, patients in the adaptive designs 2 and 3 have a better chance to survive than in Adaptive Design 1.
(ii) Theorem 1 says that the number of patients of each treatment is about v 
A SIMULATED COMPARISON OF THREE DESIGNS
In order to demonstrate the performance of the new design, some simulations are conducted to compare the three designs: (i) design A: Wei's GFU model (GFU model 1); (ii) design B: the design proposed by Andersen, Faries and Tamura (1994); and (iii) design C: the Adaptive Design 3. We compare patient allocation numbers and the average success probability among the three designs.
We consider four treatments and two different starting urn configurations, :=1 and :=5 in the simulation. The total number of patients (sample size) n=100 is used in the simulation. 10000 replications of each situation were run in S-Plus (version 4.0). The result of Table I is based on n=100, :=5 and P=(.3, .5, .5, .7) and (.1, .1., .1, .7), respectively. Table II  is the same as Table I except :=1. It is clear that both designs B and C perform better than the design A in term of success outcomes. At the same time, both designs B and C give quite balanced allocation numbers to each treatment. When the success probabilities of the treatments are similar, designs B and C provide similar results. When the success probabilities of the treatments are very different, the design C provides better results than design B for the case :=5.
From the standard deviation of the allocation numbers and the success numbers, we find that designs A and C have smaller standard deviation than design B. With the starting configuration :=1, the allocation number drifts faster for the better treatment, but the standard deviation tends to be larger. The design B has the largest standard deviation. Simulations for n=50 were also conducted in our study and the results are very similar as those in Tables I and II. Note. n=100, :=1, and P=(.3, .5, .5, .7) and (.1, .1., .1, .7), respectively.
